417 related articles for article (PubMed ID: 22240029)
41. Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.
Kotoula V; Bobos M; Alexopoulou Z; Papadimitriou C; Papadopoulou K; Charalambous E; Tsolaki E; Xepapadakis G; Nicolaou I; Papaspirou I; Aravantinos G; Christodoulou C; Efstratiou I; Gogas H; Fountzilas G
PLoS One; 2014; 9(8):e103707. PubMed ID: 25098819
[TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Ginzac A; Molnar I; Durando X; Motte Rouge T; Petit T; D'hondt V; Campone M; Bonichon-Lamichhane N; Venat Bouvet L; Levy C; Augereau P; Pistilli B; Arsene O; Jouannaud C; Nguyen S; Cayre A; Tixier L; Mahier Ait Oukhatar C; Nabholtz JM; Penault-Llorca F; Mouret-Reynier MA
Breast Cancer Res Treat; 2024 Jun; 205(2):267-279. PubMed ID: 38453781
[TBL] [Abstract][Full Text] [Related]
43. TOP2A gene copy number change in breast cancer.
Engstrøm MJ; Ytterhus B; Vatten LJ; Opdahl S; Bofin AM
J Clin Pathol; 2014 May; 67(5):420-5. PubMed ID: 24403186
[TBL] [Abstract][Full Text] [Related]
44. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
Nielsen KV; Ejlertsen B; Møller S; Jørgensen JT; Knoop A; Knudsen H; Mouridsen HT
Acta Oncol; 2008; 47(4):725-34. PubMed ID: 18465341
[TBL] [Abstract][Full Text] [Related]
45. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ
Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
[TBL] [Abstract][Full Text] [Related]
46. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
Varga Z; Moelans CB; Zuerrer-Hardi U; Ramach C; Behnke S; Kristiansen G; Moch H
Breast Cancer Res Treat; 2012 Jun; 133(3):929-35. PubMed ID: 22083232
[TBL] [Abstract][Full Text] [Related]
47. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
Wu Y; Han Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Xu H; Wang Y; Ma F; Wang J; Xu B
Breast Cancer Res Treat; 2022 Jun; 193(2):381-392. PubMed ID: 35297009
[TBL] [Abstract][Full Text] [Related]
48. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
[TBL] [Abstract][Full Text] [Related]
49. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
[TBL] [Abstract][Full Text] [Related]
50. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
Meng H; Chen R; Li W; Xu L; Xu L
Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
[TBL] [Abstract][Full Text] [Related]
51. Assessment of topoisomerase II-alpha gene status by dual color chromogenic
Neama RAA; Habib MA; Ali SA; Al-Khafaji AH; Alqanbar MF
Indian J Pathol Microbiol; 2017; 60(4):475-480. PubMed ID: 29323058
[TBL] [Abstract][Full Text] [Related]
52. HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas.
Aumayr K; Klatte T; Neudert B; Birner P; Shariat S; Schmidinger M; Susani M; Haitel A
Pathol Oncol Res; 2018 Jul; 24(3):575-581. PubMed ID: 28755093
[TBL] [Abstract][Full Text] [Related]
53. HER-2, TOP2A and chromosome 17 alterations in breast cancer.
Beser AR; Tuzlali S; Guzey D; Dolek Guler S; Hacihanefioglu S; Dalay N
Pathol Oncol Res; 2007; 13(3):180-5. PubMed ID: 17922046
[TBL] [Abstract][Full Text] [Related]
54. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
Romero A; Martín M; Cheang MC; López García-Asenjo JA; Oliva B; He X; de la Hoya M; García Sáenz JÁ; Arroyo Fernández M; Díaz Rubio E; Perou CM; Caldés Llopis T
Am J Pathol; 2011 Apr; 178(4):1453-60. PubMed ID: 21435434
[TBL] [Abstract][Full Text] [Related]
55. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
Arriola E; Marchio C; Tan DS; Drury SC; Lambros MB; Natrajan R; Rodriguez-Pinilla SM; Mackay A; Tamber N; Fenwick K; Jones C; Dowsett M; Ashworth A; Reis-Filho JS
Lab Invest; 2008 May; 88(5):491-503. PubMed ID: 18332872
[TBL] [Abstract][Full Text] [Related]
56. TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer.
Moretti E; Desmedt C; Biagioni C; Regan MM; Oakman C; Larsimont D; Galardi F; Piccart-Gebhart M; Sotiriou C; Rimm DL; Di Leo A
Future Oncol; 2013 Oct; 9(10):1477-87. PubMed ID: 24106899
[TBL] [Abstract][Full Text] [Related]
57. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
[TBL] [Abstract][Full Text] [Related]
58. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
[TBL] [Abstract][Full Text] [Related]
59. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Liu L; Li XR; Hu YH; Zhang J
Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
[TBL] [Abstract][Full Text] [Related]
60. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
Hannemann J; Kristel P; van Tinteren H; Bontenbal M; van Hoesel QG; Smit WM; Nooij MA; Voest EE; van der Wall E; Hupperets P; de Vries EG; Rodenhuis S; van de Vijver MJ
Br J Cancer; 2006 Nov; 95(10):1334-41. PubMed ID: 17088909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
